[HTML][HTML] Treatment for metastatic nasopharyngeal carcinoma
Y Bensouda, W Kaikani, N Ahbeddou, R Rahhali… - European annals of …, 2011 - Elsevier
Nasopharyngeal carcinoma (NPC) is a specific entity different from head and neck
carcinoma. Incidence is higher in South-East Asia and North Africa. Prognosis, especially for …
carcinoma. Incidence is higher in South-East Asia and North Africa. Prognosis, especially for …
Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review
Background: The majority of published studies in recurrent or metastatic nasopharyngeal
carcinoma (RM-NPC) are single-arm trials. Reliable modelling of progression-free survival …
carcinoma (RM-NPC) are single-arm trials. Reliable modelling of progression-free survival …
Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma
Y Jin, XY Cai, YX Shi, XY Xia, YC Cai, Y Cao… - Journal of cancer …, 2012 - Springer
Background and objective No randomized trial has been reported comparing different
chemotherapy regimens on disseminated nasopharyngeal carcinoma (NPC). This study …
chemotherapy regimens on disseminated nasopharyngeal carcinoma (NPC). This study …
Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma–How far have we achieved?
V Lee, D Kwong, TW Leung, KO Lam, CC Tong… - Critical reviews in …, 2017 - Elsevier
Nasopharyngeal carcinoma (NPC) is endemic in Southern China, Taiwan, Malaysia,
Singapore, North Africa and Alaska. About 30% of NPC patients develop recurrence or …
Singapore, North Africa and Alaska. About 30% of NPC patients develop recurrence or …
Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma
C Chen, F Wang, X An, H Luo, Z Wang, Y Liang… - Cancer chemotherapy …, 2013 - Springer
Purpose Platinum-based chemotherapy is the recognized first-line treatment for metastatic
nasopharyngeal carcinoma (NPC). However, no standard treatment regimens have been …
nasopharyngeal carcinoma (NPC). However, no standard treatment regimens have been …
[HTML][HTML] The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis
SX Ma, T Zhou, Y Huang, YP Yang… - Annals of …, 2018 - ncbi.nlm.nih.gov
Background The standard first-line chemotherapy for patients with recurrent or metastatic
nasopharyngeal carcinoma (R/M NPC) has not been well established. We conducted a …
nasopharyngeal carcinoma (R/M NPC) has not been well established. We conducted a …
Salvage gemcitabine–vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy
C Chen, F Wang, Z Wang, X An, H Luo, L Zhang… - Oral oncology, 2012 - Elsevier
OBJECTIVES: Platinum-based chemotherapy is the recognized first-line treatment for
metastatic nasopharyngeal carcinoma (NPC). However there is no standard second-line …
metastatic nasopharyngeal carcinoma (NPC). However there is no standard second-line …
Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma
J Wang, J Li, X Hong, W Tang, X Hu, B Wang, Y Gu - Oral oncology, 2008 - Elsevier
To evaluate the efficacy and toxicity of gemcitabine plus cisplatin (GC) chemotherapy in
patients with recurrent and metastatic nasopharyngeal carcinoma (NPC), 75 patients of …
patients with recurrent and metastatic nasopharyngeal carcinoma (NPC), 75 patients of …
Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
Y Huang, W Liang, Y Yang, L Zhao, H Zhao, X Wu… - BMC cancer, 2016 - Springer
Abstract Background This phase I/II study aimed to determine the maximum tolerated dose
(MTD) of nanoparticle albumin-bound paclitaxel (nab®-paclitaxel) plus cisplatin as treatment …
(MTD) of nanoparticle albumin-bound paclitaxel (nab®-paclitaxel) plus cisplatin as treatment …
An exploratory study of refining TNM-8 M1 categories and prognostic subgroups using plasma EBV DNA for previously untreated de novo metastatic nasopharyngeal …
SK Chan, B O'Sullivan, SH Huang, TC Chau, KO Lam… - Cancers, 2022 - mdpi.com
Simple Summary Patients with de novo metastatic (M1) nasopharyngeal carcinoma (NPC) at
presentation is a heterogeneous group of the population who have a diverse range of …
presentation is a heterogeneous group of the population who have a diverse range of …